183 related articles for article (PubMed ID: 22773122)
1. Neoantigen and tumor antigen-specific immunity transferred from immunized donors is detectable early after allogeneic transplantation in myeloma patients.
Foglietta M; Neelapu SS; Kwak LW; Jiang Y; Nattamai D; Lee ST; Fowler DH; Sportes C; Gress RE; Steinberg SM; Vence LM; Radvanyi L; Dwyer KC; Qazilbash MH; Bryant RN; Bishop MR
Bone Marrow Transplant; 2013 Feb; 48(2):269-77. PubMed ID: 22773122
[TBL] [Abstract][Full Text] [Related]
2. Tumor antigen immunization of sibling stem cell transplant donors in multiple myeloma.
Neelapu SS; Munshi NC; Jagannath S; Watson TM; Pennington R; Reynolds C; Barlogie B; Kwak LW
Bone Marrow Transplant; 2005 Aug; 36(4):315-23. PubMed ID: 15968284
[TBL] [Abstract][Full Text] [Related]
3. Idiotype vaccination in human myeloma: generation of tumor-specific immune responses after high-dose chemotherapy.
Massaia M; Borrione P; Battaglio S; Mariani S; Beggiato E; Napoli P; Voena C; Bianchi A; Coscia M; Besostri B; Peola S; Stiefel T; Even J; Novero D; Boccadoro M; Pileri A
Blood; 1999 Jul; 94(2):673-83. PubMed ID: 10397734
[TBL] [Abstract][Full Text] [Related]
4. Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma--a feasibility study.
Reichardt VL; Okada CY; Liso A; Benike CJ; Stockerl-Goldstein KE; Engleman EG; Blume KG; Levy R
Blood; 1999 Apr; 93(7):2411-9. PubMed ID: 10090953
[TBL] [Abstract][Full Text] [Related]
5. Combined vaccination with idiotype-pulsed allogeneic dendritic cells and soluble protein idiotype for multiple myeloma patients relapsing after reduced-intensity conditioning allogeneic stem cell transplantation.
Bendandi M; Rodríguez-Calvillo M; Inogés S; López-Díaz de Cerio A; Pérez-Simón JA; Rodríguez-Caballero A; García-Montero A; Almeida J; Zabalegui N; Giraldo P; San Miguel J; Orfao A
Leuk Lymphoma; 2006 Jan; 47(1):29-37. PubMed ID: 16321824
[TBL] [Abstract][Full Text] [Related]
6. Idiotype vaccination using dendritic cells after autologous peripheral blood progenitor cell transplantation for multiple myeloma.
Liso A; Stockerl-Goldstein KE; Auffermann-Gretzinger S; Benike CJ; Reichardt V; van Beckhoven A; Rajapaksa R; Engleman EG; Blume KG; Levy R
Biol Blood Marrow Transplant; 2000; 6(6):621-7. PubMed ID: 11128812
[TBL] [Abstract][Full Text] [Related]
7. Phase I/II clinical trial of sequential subcutaneous and intravenous delivery of dendritic cell vaccination for refractory multiple myeloma using patient-specific tumour idiotype protein or idiotype (VDJ)-derived class I-restricted peptides.
Curti A; Tosi P; Comoli P; Terragna C; Ferri E; Cellini C; Massaia M; D'Addio A; Giudice V; Di Bello C; Cavo M; Conte R; Gugliotta G; Baccarani M; Lemoli RM
Br J Haematol; 2007 Nov; 139(3):415-24. PubMed ID: 17910631
[TBL] [Abstract][Full Text] [Related]
8. Long-term follow-up of idiotype vaccination in human myeloma as a maintenance therapy after high-dose chemotherapy.
Coscia M; Mariani S; Battaglio S; Di Bello C; Fiore F; Foglietta M; Pileri A; Boccadoro M; Massaia M
Leukemia; 2004 Jan; 18(1):139-45. PubMed ID: 14574332
[TBL] [Abstract][Full Text] [Related]
9. Transfer of myeloma idiotype-specific immunity from an actively immunised marrow donor.
Kwak LW; Taub DD; Duffey PL; Bensinger WI; Bryant EM; Reynolds CW; Longo DL
Lancet; 1995 Apr; 345(8956):1016-20. PubMed ID: 7723498
[TBL] [Abstract][Full Text] [Related]
10. Cancer-testis antigen 7 expression and immune responses following allogeneic stem cell transplantation for multiple myeloma.
Tyler EM; Jungbluth AA; Gnjatic S; O'Reilly RJ; Koehne G
Cancer Immunol Res; 2014 Jun; 2(6):547-58. PubMed ID: 24894092
[TBL] [Abstract][Full Text] [Related]
11. A phase I/II minor histocompatibility antigen-loaded dendritic cell vaccination trial to safely improve the efficacy of donor lymphocyte infusions in myeloma.
Franssen LE; Roeven MWH; Hobo W; Doorn R; Oostvogels R; Falkenburg JHF; van de Donk NW; Kester MGD; Fredrix H; Westinga K; Slaper-Cortenbach I; Spierings E; Kersten MJ; Dolstra H; Mutis T; Schaap N; Lokhorst HM
Bone Marrow Transplant; 2017 Oct; 52(10):1378-1383. PubMed ID: 28581468
[TBL] [Abstract][Full Text] [Related]
12. Idiotype vaccination following ABMT can stimulate specific anti-idiotype immune responses in patients with B-cell lymphoma.
Davis TA; Hsu FJ; Caspar CB; van Beckhoven A; Czerwinsk DK; Liles TM; Taidi B; Benike CJ; Engleman EG; Levy R
Biol Blood Marrow Transplant; 2001; 7(9):517-22. PubMed ID: 11669219
[TBL] [Abstract][Full Text] [Related]
13. Listeriolysin O is an improved protein carrier for lymphoma immunoglobulin idiotype and provides systemic protection against 38C13 lymphoma.
Neeson P; Pan ZK; Paterson Y
Cancer Immunol Immunother; 2008 Apr; 57(4):493-505. PubMed ID: 17876582
[TBL] [Abstract][Full Text] [Related]
14. A randomized phase 2 trial of idiotype vaccination and adoptive autologous T-cell transfer in patients with multiple myeloma.
Qazilbash MH; Saini NY; Cha SC; Wang Z; Stadtmauer EA; Baladandayuthapani V; Lin H; Tross B; Honhar M; Rao SS; Kim K; Popescu M; Szymura S; Zhang T; Anderson A; Bashir Q; Shpall EJ; Orlowski RZ; Levine BL; Kerr N; Garfall A; Cohen A; Vogl DT; Dengel K; June CH; Champlin R; Kwak LW
Blood; 2022 Mar; 139(9):1289-1301. PubMed ID: 34521108
[TBL] [Abstract][Full Text] [Related]
15. Transfer of idiotypic protein primed allogeneic marrow grafts elicits potent graft-versus-myeloma effects in mice.
Zeis M; Steinmann J; Petrela E; Hartung G; Schmitz N; Uharek L
Bone Marrow Transplant; 2001 Feb; 27(3):279-85. PubMed ID: 11277175
[TBL] [Abstract][Full Text] [Related]
16. Idiotype protein-pulsed dendritic cells produce strong anti-myeloma effects after syngeneic stem cell transplantation in mice.
Zeis M; Frenzke H; Schmitz N; Uharek L; Steinmann J
Bone Marrow Transplant; 2002 Feb; 29(3):213-21. PubMed ID: 11859393
[TBL] [Abstract][Full Text] [Related]
17. Targeting human B-cell malignancies through Ig light chain-specific cytotoxic T lymphocytes.
Weng J; Cha SC; Matsueda S; Alatrash G; Popescu MS; Yi Q; Molldrem JJ; Wang M; Neelapu SS; Kwak LW
Clin Cancer Res; 2011 Sep; 17(18):5945-52. PubMed ID: 21813633
[TBL] [Abstract][Full Text] [Related]
18. Detection of keyhole limpet hemocyanin (KLH)-specific immune responses by intracellular cytokine assay in patients vaccinated with idiotype-KLH vaccine.
Neelapu SS; Baskar S; Kwak LW
J Cancer Res Clin Oncol; 2001 Oct; 127 Suppl 2():R14-9. PubMed ID: 11768619
[TBL] [Abstract][Full Text] [Related]
19. Tumor-specific recognition of human myeloma cells by idiotype-induced CD8(+) T cells.
Li Y; Bendandi M; Deng Y; Dunbar C; Munshi N; Jagannath S; Kwak LW; Lyerly HK
Blood; 2000 Oct; 96(8):2828-33. PubMed ID: 11023518
[TBL] [Abstract][Full Text] [Related]
20. Partial T cell-depleted allogeneic stem cell transplantation following reduced-intensity conditioning creates a platform for immunotherapy with donor lymphocyte infusion and recipient dendritic cell vaccination in multiple myeloma.
Levenga H; Schaap N; Maas F; Esendam B; Fredrix H; Greupink-Draaisma A; de Witte T; Dolstra H; Raymakers R
Biol Blood Marrow Transplant; 2010 Mar; 16(3):320-32. PubMed ID: 19835972
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]